Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III randomized comparison study of vinorelbine, gemcitabine, and docetaxel versus paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.

Next Previous
Trial Profile

Phase III randomized comparison study of vinorelbine, gemcitabine, and docetaxel versus paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vinorelbine (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 17 Sep 2013 Biomarkers information updated
  • 17 Aug 2011 Quality-of-life results published in the BMC Cancer.
  • 10 Nov 2009 Actual initiation date changed from Apr 2004 to Mar 2001 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top